Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroGen (GB:0IL8)
LSE:0IL8
FibroGen (0IL8) Share Price & Analysis
1 Followers
0IL8 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.34 - $20.23
Previous Close$1.31
Volume16.51K
Average Volume (3M)56.86K
Market Cap
$125.44M
Enterprise Value$84.37M
Total Cash (Recent Filing)$235.59M
Total Debt (Recent Filing)$152.55M
Price to Earnings (P/E)N/A
Beta1.59
Next Earnings
May 06, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding98,771,247
10 Day Avg. Volume93
30 Day Avg. Volume56,859
Standard Deviation0.16
R-Squared0.06
Alpha0.00961
Financial Highlights & Ratios
Price to Book (P/B)-0.63
Price to Sales (P/S)174.84
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit0.65
Enterprise Value/Ebitda-0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering1
FibroGen News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMultiple oncology readouts are expected over the coming quarters.
Market PotentialHigh unmet medical need in pancreatic cancer may indicate significant upside potential from clinical success.
Product PipelineInvestors expected to look beyond the revenue miss due to upcoming updates from the late and early stage oncology pipeline.
Bears Say
Clinical Trial ResultsUpdated Phase 1 data incrementally worsen vs. earlier data, showing less benefit among efficacy evaluable patients.
Drug EfficacyRecent misses by pamrevlumab in DMD and IPF raise mechanistic questions.
Sales PerformanceRoxadustat sales higher year-over-year but pricing cuts blunt solid volume growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
0IL8 FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest share price was $0.34 and its highest was $20.23 in the past 12 months.
What is FibroGen’s market cap?
Currently, no data Available
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is May 06, 2024 which is in 16 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Feb 26, 2024. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.425 by -$0.145.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Overvalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -$0.42.
How many shares outstanding does FibroGen have?
Currently, no data Available
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.425. Following the earnings report the stock price went up 17.318%.
Which hedge fund is a major shareholder of FibroGen?
Among the largest hedge funds holding FibroGen’s share is PRIMECAP Management Co. It holds FibroGen’s shares valued at 13M.
---
FibroGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
GB:0IL8 Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $95.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-93.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.58%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
---
0IL8 Company Deck
---
0IL8 Earnings Call
Q4 2024
0:00 / 0:00
---
0IL8 Stock 12 Months Forecast
Average Price Target
―Technical Analysis
FibroGen
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Incyte
―
Nektar Therapeutics
―
Best Analysts Covering 0IL8
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+14.76%
reiterated a sell rating 18 days ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +14.76% per trade.
---